Opioid Sparing Outcomes, Non-Opioid Alternatives To Get Spotlight From US FDA Advisory Cmte.
Executive Summary
The advisory committee will discuss a broad range of questions on a facet of FDA's opioid strategy that has received less attention than the others.
You may also be interested in...
Pain/Addiction Products Need Regulatory Streamlining To Incentivize Development, Sponsors Say
Industry speakers offer series of suggestions for ways to incentivize development of pain and addiction products at US FDA public meeting on the opioid crisis.
US FDA Faced With Suite Of Opinions Defining 'Clinically Meaningful' Opioid-Sparing Claims
Advisory committee agreed that statistically significant reduction in average opioid use and decrease in absolute amount were insufficient components on their own; a decrease in duration of use and a decrease in the amount of patients who don't need opioids received some support.
Opioid Prescribing Guidelines Put US FDA In Unfamiliar Territory
FDA has always described its role as stopping short of regulating the practice of medicine. When it comes to opioids, that is no longer the case.